Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies

ASH 2013 Annual Meeting

7 - 10 Dec 2013

Published: 8 Dec 2013

Views: 4021

Rating:

Save

Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA

During a press confernece at the 2013 ASH Annual Meeting, Dr Michael Kalos presents data on an overview of patient response in a clinical research program evaluating treatment of paediatric and adult leukaemia patients with experimental CAR genetically engineered T cells. A series of treatment cohorts were included in the analysis, including paediatric and adult patients with high-risk, treatment-resistant acute lymphocytic leukaemia and adult patients with advanced relapsed and/or treatment-resistant chronic lymphocytic leukaemia.

Read our ASH 2013 conference report for free.

Related Videos

Blinatumomab added to chemotherapy improves disease-free survival in newly...

Dr Rachel Rau - University of Washington, Seattle, USA

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

CAR-T - Choosing Wisely

Dr Gourav Gupta - Balco Medical Center, Raipur, India

CAR-T - Choosing Wisely ( Dr Gourav Gupta - Balco Medical Center, Raipur, India )

More from ecancer